Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
While many have been skeptical about TechBio in the past, the reception is changing rapidly. There's a good reason for this shift: The tech part of TechBio focuses on machine learning and artificial intelligence (AI) . Nearly every industry is undergoing an AI-fueled transformation. Biopharmaceutical development is no exception. That's great news for Recursion. Its shares have plunged more than 70% since the company's initial public offering (IPO) in 2021. But the potential for its technology and pipeline have arguably never looked as promising. Can Recursion Pharmaceuticals stock double in five years? Here's what it would take. Recursion's path to doubling Recursion Pharmaceuticals' market cap currently stands at just over $2 billion. The math is simple: To double, the company will need its market cap to increase to more than $4 billion. The best way to make this happen is for Recursion to achieve success with its pipeline programs. Recursion has five candidates in phase 2
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Nvidia Owns a 3.4% Stake in This Innovative Artificial Intelligence (AI) Stock Cathie Wood Loves [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Where Will Recursion Pharmaceuticals Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerGlobeNewswire
RXRX
Earnings
- 2/27/24 - Beat
RXRX
Sec Filings
- 4/29/24 - Form 4
- 4/25/24 - Form 3
- 4/25/24 - Form 144
- RXRX's page on the SEC website